Search Results (1 to 10 of 2264 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 631 Journal of Medical Internet Research
- 408 JMIR Research Protocols
- 234 JMIR Formative Research
- 181 JMIR mHealth and uHealth
- 112 JMIR Public Health and Surveillance
- 108 Online Journal of Public Health Informatics
- 86 JMIR Mental Health
- 85 JMIR Medical Informatics
- 58 JMIR Human Factors
- 43 JMIR Cancer
- 36 JMIR Aging
- 36 JMIR Dermatology
- 33 JMIR Medical Education
- 30 JMIR Diabetes
- 27 JMIR Serious Games
- 25 JMIR Pediatrics and Parenting
- 22 JMIR Cardio
- 20 Iproceedings
- 19 Interactive Journal of Medical Research
- 13 JMIR Infodemiology
- 12 JMIR Rehabilitation and Assistive Technologies
- 11 JMIR Perioperative Medicine
- 10 JMIR AI
- 7 Journal of Participatory Medicine
- 4 JMIR Biomedical Engineering
- 4 JMIR XR and Spatial Computing (JMXR)
- 4 JMIRx Med
- 2 JMIR Nursing
- 1 JMIR Bioinformatics and Biotechnology
- 1 JMIR Neurotechnology
- 1 Medicine 2.0
- 0 iProceedings
- 0 JMIR Preprints
- 0 JMIR Challenges
- 0 JMIR Data
- 0 JMIRx Bio
- 0 Transfer Hub (manuscript eXchange)
- 0 Asian/Pacific Island Nursing Journal
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
It was administered in doses ranging between 0.01 and 0.1 g/kg, 3 times daily either orally or intravenously (equivalent to 2.4-24 g/d for an 80 kg patient). Among patients with schizophrenia and catatonia, approximately 30 participants, the study showed a reduction of catatonic symptoms ranging from 60% to 70%. Specifically, there were improvements in anxiety, agitation, and restlessness.
JMIR Res Protoc 2025;14:e68356
Download Citation: END BibTex RIS
Example screenshots of the Study Management and Retention Tool (SMa RT) web application, including the different Combine intervention content sections: (A) log in screen, (B) study timeline, (C) intervention content home screen, (D), health resources section, (E) frequently asked questions about pre-exposure prophylaxis.
This section includes the major time points of the study (baseline, month 6, month 12, month 18, and month 24). It allows participants to see upcoming and previously completed surveys.
JMIR Res Protoc 2025;14:e69540
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Natural Language Processing for Identification of Hospitalized People Who Use Drugs: Cohort Study
The presence of any of the following criteria (ie, abbreviated with the letters B, D, M, and N) were used to qualify the hospitalizations for inclusion in the PWUD cohort:
B (Biomarkers): In line with a previous study, positive urine toxicology for drugs or medications for SUD (eg, cocaine, amphetamine, methadone, suboxone, fentanyl, opiate, oxycodone), positive HCV antibody with positive or quantifiable HCV viral load [29]
D (Diagnostic codes): Presence of ICD-9 and or ICD-10 code for overdose, substance use
JMIR AI 2025;4:e63147
Download Citation: END BibTex RIS
(D) Image quality control feature “not pass” and ungradable, due to eyelash artifacts.
There was agreement among 100% (15/15) of the participating users in the simulated clinic environment that they were able to have both eyes screened easily.
JMIR Form Res 2025;9:e70331
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section